Literature DB >> 28434371

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival.

Eli Muchtar1, Angela Dispenzieri1, Shaji K Kumar1, Francis K Buadi1, Martha Q Lacy1, Steven Zeldenrust1, Suzanne R Hayman1, Nelson Leung1,2, Taxiarchis V Kourelis1, Wilson Gonsalves1, Rajshekhar Chakraborty1,3, Steven Russell1, David Dingli1, John A Lust1, Yi Lin1, Prashant Kapoor1, Ronald Go1, Robert A Kyle1, S Vincent Rajkumar1, Morie A Gertz1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28434371     DOI: 10.1080/13506129.2016.1277696

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


× No keyword cloud information.
  2 in total

Review 1.  Biomarkers in AL Amyloidosis.

Authors:  Despina Fotiou; Foteini Theodorakakou; Efstathios Kastritis
Journal:  Int J Mol Sci       Date:  2021-10-09       Impact factor: 5.923

2.  The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.

Authors:  Holly Lee; Jason Tay; Peter Duggan; Sylvia McCulloch; Paola Neri; Nizar J Bahlis; Victor H Jimenez-Zepeda
Journal:  Eur J Haematol       Date:  2020-11-29       Impact factor: 3.674

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.